Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine
Autor: | Correa-Basurto José, Martinez-Archundia Marlet, García-Machorro Jazmín, Ramírez-Salinas Gema Lizbeth |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
COVID-19 Vaccines
In silico coronavirus Epitopes T-Lymphocyte Biology medicine.disease_cause Genome Epitope Virus Viral entry Structural Biology vaccine medicine Humans Molecular Biology spike glycoprotein Glycoproteins Coronavirus chemistry.chemical_classification SARS-CoV-2 COVID-19 General Medicine Acquired immune system Virology chemistry Spike Glycoprotein Coronavirus Epitopes B-Lymphocyte Glycoprotein Research Article |
Zdroj: | Journal of Biomolecular Structure and Dynamics Journal of Biomolecular Structure & Dynamics |
ISSN: | 1538-0254 0739-1102 |
DOI: | 10.1080/07391102.2020.1780944 |
Popis: | The Coronavirus disease named COVID-19 is caused by the virus reported in 2019 first identified in China. The cases of this disease have increased and as of June 1st, 2020 there are more than 216 countries affected. Pharmacological treatments have been proposed based on the resemblance of the HIV virus. With regard to prevention there is no vaccine, thus, we proposed to explore the spike protein due to its presence on the viral surface, and it also contains the putative viral entry receptor as well as the fusion peptide (important in the genome release). In this work we have employed In Silico techniques such as immunoinformatics tools which permit the identification of potential immunogenic regions on the viral surface (spike glycoprotein). From these analyses, we identified four epitopes E332-370, E627-651, E440-464 and E694-715 that accomplish essential features such as promiscuity, conservation grade, exposure and universality, and they also form stable complexes with MHCII molecule. We suggest that these epitopes could generate a specific immune response, and thus, they could be used for future applications such as the design of new epitope vaccines against the SARS-CoV-2. Communicated by Ramaswamy H. Sarma |
Databáze: | OpenAIRE |
Externí odkaz: |